Drug Screening for Pelizaeus-Merzbacher Disease by Quantifying the Total Levels and Membrane Localization of PLP1

Overview

Journal Mol Genet Metab Rep

Specialty Endocrinology

Date 2019 May 22

PMID 31110947

Citations 3

Authors

Takeshi Kouga

Shiro Koizume

Shiho Aoki

Eriko Jimbo

Takanori Yamagata

Ken Inoue

Hitoshi Osaka

Affiliations

Soon will be listed here.

Abstract

Background: Pelizaeus-Merzbacher disease (PMD) is caused by point mutations or copy number changes in the proteolipid protein 1 gene (). is exclusively localized in the myelin sheath of oligodendrocytes. Amino acid-substituted PLP1 protein is unable to fold properly and is subsequently degraded and/or restrictedly translated, resulting in a decrease in the PLP1 protein level and a failure to localize to the membrane. Furthermore, misfolded proteins increase the burden on the intracellular quality control system and trafficking, finally resulting in cell apoptosis. The objective of this study was to identify therapeutic chemicals for PMD by quantifying the total levels and membrane localization of PLP1.

Method: We established a cell line stably expressing PLP1 fused with green fluorescent protein in oligodendrocyte-derived MO3.13 cells. We screened a chemical library composed of drugs approved for central nervous system disorders that increased both the total intensity of PLP1 in the whole cell and the cell membrane localization. We analyzed the change in the endoplasmic reticulum (ER) stress and the gene expression of candidate chemicals using a micro-array analysis. Finally, we tested the in vivo effectiveness using myelin synthesis deficient () mice with .

Results And Conclusion: Piracetam significantly increased the PLP1 intensity and membrane localization and decreased the ER stress. It was also shown to reverse the gene expression changes induced by PLP1 in a micro-array analysis. However, in vivo treatment of piracetam did not improve the survival of mice (Plp1).

Citing Articles

Pelizaeus-Merzbacher disease: on the cusp of myelin medicine.

Elitt M, Tesar P Trends Mol Med. 2024; 30(5):459-470.

PMID: 38582621 PMC: 11081862. DOI: 10.1016/j.molmed.2024.03.005.

Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis.

Yang Y, Chu L, Zeng Z, Xu S, Yang H, Zhang X Bioengineered. 2021; 12(1):6643-6654.

PMID: 34516348 PMC: 8806527. DOI: 10.1080/21655979.2021.1975980.

Environmental and Nutritional "Stressors" and Oligodendrocyte Dysfunction: Role of Mitochondrial and Endoplasmatic Reticulum Impairment.

Maiuolo J, Gliozzi M, Musolino V, Carresi C, Nucera S, Scicchitano M Biomedicines. 2020; 8(12).

PMID: 33265917 PMC: 7760976. DOI: 10.3390/biomedicines8120553.

References

Muller W, Eckert G, Eckert A . Piracetam: novelty in a unique mode of action. Pharmacopsychiatry. 1999; 32 Suppl 1:2-9. DOI: 10.1055/s-2007-979230. View

Simons M, Kramer E, Thiele C, STOFFEL W, Trotter J . Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J Cell Biol. 2000; 151(1):143-54. PMC: 2189802. DOI: 10.1083/jcb.151.1.143. View

Greer J, Lees M . Myelin proteolipid protein--the first 50 years. Int J Biochem Cell Biol. 2002; 34(3):211-5. DOI: 10.1016/s1357-2725(01)00136-4. View

Simons M, Kramer E, Macchi P, Rathke-Hartlieb S, Trotter J, Nave K . Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J Cell Biol. 2002; 157(2):327-36. PMC: 2199249. DOI: 10.1083/jcb.200110138. View

Inoue K . PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics. 2005; 6(1):1-16. DOI: 10.1007/s10048-004-0207-y. View

Swanton E, Holland A, High S, Woodman P . Disease-associated mutations cause premature oligomerization of myelin proteolipid protein in the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2005; 102(12):4342-7. PMC: 555485. DOI: 10.1073/pnas.0407287102. View

Winblad B . Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005; 11(2):169-82. PMC: 6741724. DOI: 10.1111/j.1527-3458.2005.tb00268.x. View

Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Muller W . Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol. 2005; 147(2):199-208. PMC: 1615864. DOI: 10.1038/sj.bjp.0706459. View

Winnicka K, Tomasiak M, Bielawska A . Piracetam--an old drug with novel properties?. Acta Pol Pharm. 2006; 62(5):405-9. View

10.

Koizume S, Takizawa S, Fujita K, Aida N, Yamashita S, Miyagi Y . Aberrant trafficking of a proteolipid protein in a mild Pelizaeus-Merzbacher disease. Neuroscience. 2006; 141(4):1861-9. DOI: 10.1016/j.neuroscience.2006.05.067. View

11.

Abdel Salam O . Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice. Pharmacol Rep. 2006; 58(5):680-91. View

12.

Garbern J . Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci. 2006; 64(1):50-65. PMC: 11136140. DOI: 10.1007/s00018-006-6182-8. View

13.

Karim S, Barrie J, McCulloch M, Montague P, Edgar J, Kirkham D . PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus-Merzbacher disease. Glia. 2006; 55(4):341-51. DOI: 10.1002/glia.20465. View

14.

Pham-Dinh D, Birling M, Roussel G, Dautigny A, Nussbaum J . Proteolipid DM-20 predominates over PLP in peripheral nervous system. Neuroreport. 1991; 2(2):89-92. DOI: 10.1097/00001756-199102000-00006. View

15.

Baens M, Noels H, Broeckx V, Hagens S, Fevery S, Billiau A . The dark side of EGFP: defective polyubiquitination. PLoS One. 2006; 1:e54. PMC: 1762387. DOI: 10.1371/journal.pone.0000054. View

16.

Yamagishi S, Koyama Y, Katayama T, Taniguchi M, Hitomi J, Kato M . An in vitro model for Lewy body-like hyaline inclusion/astrocytic hyaline inclusion: induction by ER stress with an ALS-linked SOD1 mutation. PLoS One. 2007; 2(10):e1030. PMC: 2000355. DOI: 10.1371/journal.pone.0001030. View

17.

Finch A, Sedgley K, Caunt C, McArdle C . Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines. J Endocrinol. 2008; 196(2):353-67. PMC: 2229628. DOI: 10.1677/JOE-07-0471. View

18.

Woodward K . The molecular and cellular defects underlying Pelizaeus-Merzbacher disease. Expert Rev Mol Med. 2008; 10:e14. DOI: 10.1017/S1462399408000677. View

19.

Anderl J, Redpath S, Ball A . A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity. J Vis Exp. 2009; (27). PMC: 3253581. DOI: 10.3791/1173. View

20.

Iwawaki T, Akai R, Yamanaka S, Kohno K . Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability. Proc Natl Acad Sci U S A. 2009; 106(39):16657-62. PMC: 2757843. DOI: 10.1073/pnas.0903775106. View